1. Introduction {#s0005}
===============

Metabolic disorders (MetDs) such as metabolic syndrome, obesity, and type 2 diabetes (T2D) have become a pressing health apprehension worldwide due to their increasing prevalence and high mortality rate, and even more recently to their ability to escalate the pathology of neurological and psychiatric disorders ([@bb0025], [@bb0145], [@bb0080], [@bb0115]). Among the potential culprits for the rising epidemic of metabolic and brain disorders are dietary components introduced through industrialization ([@bb0050], [@bb0195]). In particular, fructose, which has been widely used as a "safe and healthy" sweetener in soft drinks and processed foods in the past decades, is emerging as a significant contributor to MetDs in humans ([@bb0125], [@bb0120]). Fructose-induced MeDs has been shown to reduce hippocampal-dependent memory ([@bb0005]) and to worsen the pathology of brain disorders in rodents ([@bb0010]). Conversely, the omega-3 fatty acid docosahexaenoic acid (DHA) has been shown to attenuate MetDs ([@bb0190], [@bb0225], [@bb0065]), and to counteract the deleterious effects of fructose on brain function and plasticity ([@bb0030], [@bb0005]). Our understanding of the molecular mechanisms underlying the actions of fructose and DHA on MetDs and brain disorders has been limited by conventional approaches focusing on isolated molecular events. This limitation has delayed major advances in the utilization of nutrient-based strategies for the prevention and treatment of common complex disorders.

As fundamental aspects of gene regulation, disruptions in epigenomic reprogramming, transcript abundance, alternative splicing, and gene--gene interactions are increasingly recognized as core aspects of wide-ranging pathogenesis ([@bb0055], [@bb0265], [@bb0170], [@bb0140], [@bb0130], [@bb0250]). Systems nutrigenomics is emerging as a powerful approach to reveal the hidden aspects of pathogenesis under dietary modulation ([@bb0270], [@bb0070], [@bb0155]). Here we apply systems nutrigenomics to unveil the multidimensional molecular interactions driven by fructose and DHA that regulate pathogenesis and recovery, and to provide proof-of-principle on the potential of systems nutrigenomics to guide personalized medicine. The comparative account of nutrigenomics signals between fructose and DHA is crucial to understand how select diets impact the molecular substrates governing the balance between normal brain function and disease, and holds potential for guiding effective preventative and therapeutic strategies to mitigate common human diseases.

2. Materials and Methods {#s0010}
========================

We describe essential methods in the main text and detailed experimental procedures are available in the Supplemental Materials.

2.1. Overall Study Design {#s0015}
-------------------------

As depicted in the analysis flow in [Fig. 1](#f0005){ref-type="fig"}, we focus our study on two key regions in the rodent brain that are important for the regulation of metabolism (hypothalamus) and cognition (hippocampus), and therefore can play a major role in fructose-induced metabolic and brain dysregulation as well as DHA-mediated recovery. We analyzed the transcriptome and DNA methylome using next generation sequencing, followed by investigation of the regulatory relationship between the methylome and transcriptome. Network approaches were then applied to model gene--gene interactions and to predict essential perturbation or regulatory points. Knockout mouse models were subsequently used to validate the predicted regulatory genes with regard to their ability to modulate metabolic and behavior phenotypes. To infer translatability to human pathophysiology, we assessed the intersection of the molecular signals from our rodent models with human genome-wide association studies (GWAS) of metabolic and brain disorders.

2.2. Rat model of fructose consumption and DHA supplementation {#s0020}
--------------------------------------------------------------

Male Sprague--Dawley rats (Charles River Laboratories, Inc., MA, USA) of 2 months old weighing 200-220 g were randomly assigned to 15% fructose treatment (n = 8, 15% *w*/*v* fructose in the drinking water), 15% fructose plus an omega-3 fatty acid diet rich in DHA (n = 8; 0.5% of flaxseed oil supplying ALA and 1.2% of DHA capsule oil, Nordic Naturals, Inc., CA, USA), or a control group (n = 8, without fructose in drinking water or DHA supplement) for six weeks. Sample size was chosen to yield \> 80% statistical power to detect 30% between-group difference with 10% within-group difference in a phenotype using two-sided Student\'s *t*-test. The rats were singly housed in polyacrylic cages with free access to water and their respective diets, and maintained under standard housing conditions (room temperature 22--24 °C) with 12 h light/dark cycle. Daily food and drink intake were monitored. The fructose intake level is approximately equivalent to long-term daily consumption of 130 g sugar in 1--2 l soda drinks in a 60 kg human. The total fat content in the control and DHA diets was 10 g per 100 g of diet. The rats were then examined for changes in MetD-related phenotypes (serum levels of insulin, glucose, and triglycerides, and insulin resistance index (fasting glucose \[mg/dl\] × fasting insulin \[ng/ml\] / 16.31)). Rats were trained in the Barnes maze test for 5 days to learn the task prior to diet treatment and then tested for memory retention in the Barnes Maze after 6 weeks of treatment as previously described ([@bb0005]). Mice were sacrificed, and hypothalamus and hippocampus were dissected out, flash frozen, and stored at − 70 °C for transcriptome and DNA methylome sequencing experiments.

2.3. RNA Sequencing (RNA-Seq) and Data Analyses {#s0025}
-----------------------------------------------

RNA-Seq libraries were prepared for 24 RNA samples (n = 4 per treatment group per brain region) and sequenced in paired-end mode by HiSeq 2000 (Illumina Inc., CA, USA) as detailed in Supplemental Materials. The short reads data were analyzed for different transcription between treatment and control groups using the Tuxedo tool package ([@bb0210]) and false discovery rate (FDR) was estimated using the q-value approach. One hypothalamus sample from the fructose group failed standard quality control and was removed from analysis. Genes and transcripts showing differential expression or alternative splicing at *p* \< 0.01 in each brain region were defined as a gene "signature" for further integrative analyses. The reliability of transcriptome signals at *p* \< 0.01 from RNA-Se1 was confirmed using quantitative real-time PCR (qPCR) for 12 selected genes (Supplemental Materials). Relative gene expression was represented by delta Ct = Ct~*gene*~ − Ct~*Gapdh*~. The RNA-Seq data was deposited to Gene Expression Ominbus (GEO) under accession numbers GSE59918 (control and fructose groups) and GSE 64815 (DHA).

2.4. Reduced Representation Bisulfite Sequencing (RRBS) of DNA Methylome {#s0030}
------------------------------------------------------------------------

RRBS libraries were constructed for 24 DNA samples (n = 4 per treatment group per brain region) and sequenced using an Illumina HiSeq 2500 System (Illumina Inc., CA, USA) as described in Supplemental Materials. Bisulfite-converted reads were processed using the bisulfite aligner BS Seeker2 ([@bb0090]). One hypothalamus sample from the DHA group failed standard quality control and was removed from analysis. Differential methylation between treatment and control groups was calculated using the R package methylKit ([@bb0015]) and FDR was estimated using the q-value approach. Loci with methylation levels \> 25% between groups and FDR \< 0.05 were defined as differentially methylated loci (DMLs). The potential *cis*- and *trans*-regulatory effects of DNA methylome on transcriptome were further examined (Supplemental Materials). RRBS data was deposited to GEO under accession numbers [GSE59893](ncbi-geo:GSE59893){#ir0005} (control and fructose groups) and GSE64816 (DHA).

2.5. Assessing Overlap Between Fructose Signatures and Candidate Causal Genes From Human GWAS of MetDs and Brain Disorders {#s0035}
--------------------------------------------------------------------------------------------------------------------------

We tested the consistency between the genes identified from fructose treatment in our study and those from human GWAS related to MetDs and brain functions in two ways. First, we cross-checked genes identified in our study with top GWAS candidate genes reported in the GWAS catalog (<http://www.genome.gov/gwastudies/>) ([@bb0095]) for direct overlap. Second, we used a SNP Set Enrichment Analysis (SSEA) ([@bb0130]), which goes beyond the top GWAS hits and tests the overall enrichment of the genes affected in our fructose animal model for SNPs that demonstrated disease association in humans using Kolmogorov--Smirnov (KS) test and Fisher\'s exact test. Bonferroni-corrected *p* \< 0.05 by either KS test or Fisher\'s exact test was considered significant. The detailed methods and GWAS datasets involved are described in Supplemental Materials.

2.6. Network Modeling and Identification of Key Drivers (KD) of Fructose and DHA Signatures {#s0040}
-------------------------------------------------------------------------------------------

We obtained both protein--protein interaction (PPI) networks from the HPRD database (<http://www.hprd.org>) ([@bb0110]) and tissue-specific Bayesian networks (BNs) ([@bb0275], [@bb0280]) for hypothalamus and hippocampus constructed based on genetic and transcriptomic data from multiple large-scale mouse studies (Supplemental Materials). We used the fructose or DHA signature genes identified from the RNA-Seq analysis as seeds to extract the top most connected subnetworks as described previously ([@bb0250]). The network components including nodes and edges as well as topological structures were visualized using Cytoscape ([@bb0180]). A Key Driver Analysis (KDA; detailed in Supplemental Materials) ([@bb0255], [@bb0265]) was used to identify potential key regulators for the fructose and DHA signatures based on the topology of BNs and PPI networks. Briefly, the neighboring subnetwork of each gene in a given network was first extracted and then compared with the tissue-matched fructose or DHA signature to assess the enrichment of genes in the latter using Fisher\'s exact test. Network genes that reach Bonferroni-adjusted *p* \< 0.05 were reported as KDs. KDs identified from multiple networks were ranked according to a composite score that favors KDs that are highly significant in each KDA and are consistent across network models used for KDA (Supplemental Materials).

2.7. KD Validation Using *Bgn* and *Fmod* Knockout (KO) Models {#s0045}
--------------------------------------------------------------

*Bgn* KO mice ([@bb0240]) and *Fmod* KO mice ([@bb0205]) were given as gifts from National Institute of Dental and Craniofacial Research and re-derived at the University of California, Los Angeles. Mice were housed in standard polyethylene cages (3--4 mice per cage) in an environmentally controlled room (22--24 °C) with a 12 h light/dark cycle and free access to food and water. Homozygous male KO mice (*Bgn*: n = 16, *Fmod*: n = 11) of 9-week age were tested against male wild type (WT) controls (n = 8) for phenotypic changes in metabolic (glucose tolerance, plasma lipid panel) and learning and memory traits (Barnes maze) as described in the Supplemental Materials.

2.8. Statistics {#s0050}
---------------

For metabolic and behavior phenotypes, two-sided Student\'s *t*-test was used to test statistical differences in between fructose-treated mice and control mice, or between the fructose and fructose + DHA group, or between KO mice (*Bgn* KO or *Fmod* KO) and wild-type mice. Two-way ANOVA with Holm-Sidak post hoc analysis for multiple comparisons was performed for the learning curves. For RNA-Seq, RRBS, KDA, and SSEA analyses, the statistical tests and multiple testing correction methods were described in detail under the respective method sections. All statistical and bioinformatics analyses were performed in R (<http://www.R-project.org>/).

2.9. Study Approval {#s0055}
-------------------

All experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Chancellor\'s Animal Research Committee of the University of California, Los Angeles.

3. Results {#s0060}
==========

3.1. Induction of Metabolic and Behavioral Abnormalities by Fructose and Normalization by DHA {#s0065}
---------------------------------------------------------------------------------------------

Compared to the control group (n = 8), adult rats consuming fructose (n = 8) had MetD characteristics including significantly increased blood glucose, triglycerides, insulin, and insulin resistance index ([Fig. 2](#f0010){ref-type="fig"}a). The animals on fructose also displayed impaired memory as demonstrated by prolonged latency in the Barnes Maze test ([Fig. 2](#f0010){ref-type="fig"}a). On the other hand, fructose-treated animals with DHA supplementation (DHA + fructose) showed significantly improved metabolic parameters including lower serum triglycerides, insulin, insulin resistance index, as well as improved memory as reflected by the reduced latency time in the Barnes Maze test ([Fig. 2](#f0010){ref-type="fig"}a). The measurements in the DHA + fructose group were not significantly different from the control group with no fructose treatment for triglycerides, insulin, and latency time, indicating that DHA supplementation counteracted the fructose effects. Of note, total caloric intake between groups was similar between groups.

3.2. Transcriptomic Changes in Hypothalamus and Hippocampus Induced by Fructose and Normalization by DHA {#s0070}
--------------------------------------------------------------------------------------------------------

Using RNA-Seq, we identified 581 and 146 differentially expressed genes, 352 and 79 differentially expressed transcripts, and 99 and 53 genes showing alternative exon usage in hypothalamus and hippocampus, respectively, at *p* \< 0.01 ([Dataset S1](#ec0010){ref-type="supplementary-material"}). These results support large-scale alterations in transcriptional activities affecting both differential expression and alternative splicing, and define 734 unique hypothalamic genes (312 passed FDR \< 5%) and 206 hippocampal genes (56 passed FDR \< 5%) as "fructose gene signatures". The reliability of the differentially signals at *p* \< 0.01 was supported by consistent qPCR experiments on 12 selected genes (Table S1). Among the signatures were transcription factors (e.g., *Aff3*, *Junb*, *Zbtb16*, *Tcf7l2*), epigenetic regulators (e.g., *Trmu*, *Suv420h2*, *Rgs9bp*), and alternative splicing regulators (e.g., *Bicc1*, *Prpf31*, *Rbpms*) ([Dataset S1](#ec0010){ref-type="supplementary-material"}), which may partially explain the large-scale transcriptional alterations observed.

The fructose signatures showed strong tissue-specificity, with 664 genes unique to the hypothalamus, 136 unique to the hippocampus, and 70 overlapping between tissues. In particular, only in hypothalamus we observed upregulation of *Slc2a5* (encoding the major fructose transporter GLUT5) and downregulation of *Slc2a4* (encoding the glucose transporter protein GLUT4). The signatures also differ by direction of change between the two brain compartments: 68% of hypothalamic signatures showed down-regulation compared to 42% in hippocampus. Among the overlapping genes between the two brain regions ([Dataset S1](#ec0010){ref-type="supplementary-material"}), only 6 showed consistent upregulation (*Atp5f1*, *Pnpla1*, *Pomc*, *Sepw1*, *Slc39a12*, and *Ubc*) and 5 showed consistent downregulation (*Alox15*, *Dstn*, *Rpl30*, *Slc39a4*, and *Slc5a7*). The consistent genes are involved in mitochondria function, energy balance, antioxidation, inflammation, and cognition.

Compared to the fructose group, the DHA + fructose group showed differential expression of 651 and 462 genes, 449 and 277 transcripts, and alternative exon usage for 155 and 81 genes in hypothalamus and hippocampus at *p* \< 0.01, respectively ([Dataset S1](#ec0010){ref-type="supplementary-material"}), which together define "DHA gene signatures" of 910 unique genes (382 passed FDR \< 5%) in hypothalamus and 569 unique genes (246 passed FDR \< 5%) in hippocampus. Strikingly, these DHA signatures significantly overlapped with the fructose signatures ([Table 1](#t0005){ref-type="table"}), with DHA reversing the expression of the common signatures perturbed by fructose in both brain regions ([Fig. 2](#f0010){ref-type="fig"}b; [Dataset S1](#ec0010){ref-type="supplementary-material"}).

3.3. Functional Categorization of Fructose and DHA Transcriptomic Signatures {#s0075}
----------------------------------------------------------------------------

We found enrichment of both tissue-specific and shared biological pathways between brain regions and between treatment groups (select pathways shown in [Fig. 2](#f0010){ref-type="fig"}d; full details in [Dataset S2](#ec0015){ref-type="supplementary-material"}). Fructose and DHA signatures shared similar over-represented pathways, although the direction of expression changes of the overlapping genes was predominantly opposite (exemplified in [Fig. 2](#f0010){ref-type="fig"}d insert; details in [Dataset S1](#ec0010){ref-type="supplementary-material"}). The pathways unique to hypothalamus included those highly relevant to cardiometabolic, inflammatory, and neuronal functions. The pathway affected in the hippocampus was "neurological processes". Those affected in both regions were related to extracellular matrix (ECM), adhesion, complement, and insulin-like growth factor (IGF) signaling.

3.4. Induction of DNA Methylomic Changes by Fructose and Normalization by DHA {#s0080}
-----------------------------------------------------------------------------

To identify epigenomic changes which may play a role in the transcriptomic alternation associated with fructose and DHA, we examined the DNA methylome using RRBS that measures millions of potential DNA methylation sites at single base resolution. We found that fructose consumption induced a large-scale switch of the methylation patterns in both brain regions: 734 and 810 of differentially methylated loci (DMLs) showed hypomethylation and hypermethylation in hypothalamus, respectively; 972 and 900 DMLs showed hypomethylation and hypermethylation in hippocampus at a FDR \< 5%, respectively ([Fig. 2](#f0010){ref-type="fig"}c). DHA largely reversed the fructose-induced methylation changes in these two brain regions ([Fig. 2](#f0010){ref-type="fig"}c; [Table 1](#t0005){ref-type="table"}).

3.5. Relationship Between Differential Methylation and Differential Expression {#s0085}
------------------------------------------------------------------------------

To explore the potential relationship between DMLs and gene expression, we mapped the fructose DMLs in each brain region to adjacent genes within 10 kb distance. We found 50% of DMLs to be located in the intergenic regions, 34% in the gene body (including 5′-UTR, intron, coding sequence, and 3′-UTR), and 16% in the upstream or downstream regions of the genes, with a paucity of DMLs in the promoter and transcription start site (Fig. S1; Table S2). Assessing the methylome-transcriptome relationship revealed co-localization of DMLs and gene signatures: 74 out of the 734 (10.1%) hypothalamic signature genes and 18 out of the 206 (8.7%) hippocampal signature genes co-localized with DMLs within 50 kb distance (Table S3), suggesting *cis*-regulation of gene expression by the local DMLs. Notably, some of the genes with co-localizing DMLs are transcription factors (*Aff3*, *Junb*, and *Zbtb16*) or epigenetic factors (*Parp9*) ([Dataset S3](#ec0020){ref-type="supplementary-material"}), which could in turn *trans*-regulate downstream target genes. Additionally, microRNAs adjacent (within 20 kb or 50 kb) to the DMLs had the potential to regulate 36%--45% and 17%--45% of hypothalamic and hippocampal signatures which were the predicted target genes of the corresponding microRNAs (Table S3; details of the microRNAs in [Dataset S3](#ec0020){ref-type="supplementary-material"}). These results suggest that fructose-induced DNA methylation changes could contribute to transcriptional alteration through both *cis* and *trans*-regulatory mechanisms.

3.6. Perturbation of Gene Subnetworks by Fructose and Normalization by DHA {#s0090}
--------------------------------------------------------------------------

To explore the gene--gene relations among the fructose signature genes and to identify key perturbation points of fructose, we employed two types of networks - protein--protein interaction (PPI) networks ([@bb0110]) that capture a majority of the well-known interactions between proteins, and data-driven Bayesian networks (BNs) ([@bb0275], [@bb0280]) that elucidate gene--gene regulatory relationships (detailed in [Materials and Methods](#s0010){ref-type="sec"}). Using these networks and a network topology-based key driver analysis (KDA), we identified multiple candidate key driver (KD) genes whose network neighboring genes highly overlapped with the fructose signature genes ([Dataset S4](#ec0025){ref-type="supplementary-material"}). As shown in [Fig. 3](#f0015){ref-type="fig"}, the top 5 KDs for each brain region form central hubs connecting many fructose signature genes in coherent gene subnetworks, which contained genes involved in diverse processes such as the ECM (e.g., *Col6a2*, *Lama4*, *Thbs1*, *Fmod*, *Bgn*), small molecule transporters (e.g., *Slc6a13*, *Slc22a2*, *Slc22a6*, *Slc13a3*), and forkhead transcription factors (e.g., *Foxc2*, *Foxd2*). Between the subnetworks of the two brain compartments, *Fmod*, *Bgn*, and *Foxc2* were consistent KDs revealed from our data-driven approach ([Dataset S4](#ec0025){ref-type="supplementary-material"}). Remarkably, these KDs and subnetworks were largely reversed by DHA supplementation ([Fig. 3](#f0015){ref-type="fig"}).

3.7. Validation of *Bgn* and *Fmod* as Key Regulators of MetDs and Behavioral Aberrations in KO Mouse Models {#s0095}
------------------------------------------------------------------------------------------------------------

To evaluate our network KD prediction, we used *Bgn* and *Fmod* KO mice ([@bb0240], [@bb0205]) to test the effect of perturbing these KDs on phenotypes related to MetDs and cognitive function. Compared to wild type (WT) controls, we observed significantly elevated triglyceride, total cholesterol, HDL cholesterol, and un-esterified cholesterol in the plasma of both *Bgn* and *Fmod* KO mice, significant increases in LDL cholesterol in the *Bgn* KO, and elevated free fatty acids in the *Fmod* KO ([Fig. 4](#f0020){ref-type="fig"}a). We also found decreased levels of plasma glucose, insulin, as well as insulin resistance index in *Fmod* KO ([Fig. 4](#f0020){ref-type="fig"}b--d). The intraperitoneal glucose tolerance test of *Bgn* KO demonstrated significantly lower plasma glucose at 15 min after glucose injection and a similar trend in the *Fmod* KO ([Fig. 4](#f0020){ref-type="fig"}e).

To assess the potential influence of *Bgn* and *Fmod* for spatial learning and memory, we tested the animals in the Barnes Maze. Because *Fmod* and *Bgn* KOs have been previously shown to have impaired tendon and joints which may affect latency time ([@bb0020], [@bb0040], [@bb0105]), we analyzed the Barnes Maze data by number of mistakes to eliminate the potential confound originated by differences in mobility. In addition, number of mistakes has been demonstrated as a more accurate measure of cognitive abilities in mice ([@bb0150]). During the learning phase, there was a significant effect of animal type (F~2,35~ = 10.14; *p* = 0.0003 by 2-way ANOVA) and day (F~3,105~ = 40.44; *p* \< 0.0001 by 2-way ANOVA) on the number of mistakes made in the Barnes Maze ([Fig. 4](#f0020){ref-type="fig"}f). Post hoc analysis revealed that both *Bgn* KO and *Fmod* KO made fewer mistakes compared with WT during the learning and the memory phases. Representative track plot analysis show a difference in strategy to find the escape hole ([Fig. 4](#f0020){ref-type="fig"}g, inset): the WT animals use a trial and error approach while the *Bgn* and *Fmod* KO animals follow a more direct path.

3.8. Relevance of Fructose Signatures and KDs to Human Diseases {#s0100}
---------------------------------------------------------------

To assess the relevance of our nutrigenomic signals from the rodent models to human pathophysiology, we compared the fructose signature genes as well as the KDs to human GWAS of MetDs and brain related diseases or traits. We found numerous overlapping genes between fructose signature genes and top GWAS hits in the GWAS catalog for a broad range of brain disorders and MetDs-related diseases or traits ([Dataset S4](#ec0025){ref-type="supplementary-material"}). Importantly, KDs such as *Fmod*, *Col1a2*, *Col18a1*, and *Dcn* were GWAS candidate genes associating with obesity, cardiovascular disease, metabolic syndrome, and brain morphology and cognition, respectively. When using full sets of GWAS results we had accessed for plasma lipids, T2D, systolic and diastolic blood pressure traits, cognitive traits, and bipolar disorder, we found that human orthologs of the fructose signature genes derived from both hypothalamus and the hippocampus were significantly enriched for genetic polymorphisms showing stronger associations with these diseases or traits ([Table 2](#t0010){ref-type="table"}).

4. Discussion {#s0105}
=============

In this systems nutrigenomics study, we show that fructose remodels fundamental aspects of gene regulation such as differential DNA methylation, differential gene expression, alternative splicing, and implications for microRNA alterations, all of which have the potential to impact pathogenesis. In addition, we found that fructose alters the organization of genes in brain region-specific networks interrelating cell metabolism, immune function, inflammation, and cell communication via key regulators such as the extracellular matrix genes *Bgn* and *Fmod*. Remarkably, we found that DHA supplementation was capable to reverse the genomic, epigenomic, network, and phenotypic perturbations induced by fructose via the same key drivers.

Our findings indicate that fructose and DHA induce transcriptomic reprogramming by engaging core transcription factors, splicing factors, and epigenetic modifications. For instance, fructose altered classic transcription factors such as *Tcf7l2* (the most significant and robust signal for T2D from human GWAS) ([@bb0230]) and *Zbtb16*. Additionally, \> 20% of the fructose and DHA signature genes only showed changes at isoform or alternative splicing levels but not overall expression, and alternative splicing factors such as *Bicc1*, *Prpf31*, and *Rbpms* were among the signature genes, supporting the importance of RNA splicing in the pathogenesis of human diseases highlighted recently ([@bb0235]). The involvement of epigenetic mechanisms in fructose and DHA actions was substantiated by the significant alterations in the methylome of hypothalamus and hippocampus. *cis*-Regulation of transcriptome by DNA methylation was evidenced by co-localization of a subset of signature genes with local DMLs; *trans*-regulation mechanism was supported by the co-localization of DMLs with a number of transcriptional regulators (e.g., *Aff3*, *Junb*, *Zbtb16*, and *Parp9*) and microRNAs (e.g., rno-miR-421, rno-miR-143) whose predicted target genes were enriched among the signature genes. An increasing body of evidence indicates that neurological and psychiatric disorders have an epigenetic component ([@bb0100], [@bb0215]). In particular, disruption in cell metabolism seems to be a driving force for epigenetic changes associated with cognitive function ([@bb0220]). The current results showing that DHA can counteract the broad transcriptomic and methylomic alterations induced by fructose imply that diet has the ability to regulate the susceptibility to disease by modulating the multifaceted transcriptional machinery.

Our studies also revealed broad impact of fructose and DHA on fundamental cell processes encompassing metabolism, inflammation, cell communication, and neuronal signaling, as well as critical differences between the two brain regions. For instance, the fructose and glucose transporter genes *Slc2a5* and *Slc2a4*, and a broader category of pathways including insulin signaling, cardiomyopathy, transforming growth factor (TGF) beta signaling, mitogen-activated protein kinases (MAPK) signaling, platelet-derived growth factor (PDGF) signaling, toll like receptor (TLR) signaling, brain-derived neurotropic factor (BDNF) signaling, neural cell adhesion molecule (NCAM) signaling, and axon guidance were perturbed only in the hypothalamus. In fact, most of the hypothalamic pathways have been recently implicated in leptin resistance, hypothalamic deregulation and peripheral metabolism impairment ([@bb0135], [@bb0245]). The prominent response of the hypothalamus to diets is consistent with its role as the master metabolic sensor and regulator, and the current results suggest that these actions intermingle with inflammatory and cognitive signals. In contrast, the effects of fructose on the hippocampus were prominent in pathways engaged in cognitive function and neurological processes. For instance, hippocampal signature genes *Pdc*, *Chrnb4*, and *Gch1* were previously implicated in schizophrenia ([@bb0200]), addictive behavior ([@bb0165]), attention and vigilance ([@bb0260]), and early-onset Parkinson\'s disease ([@bb0035]). The biological pathways affected in both brain regions were related to ECM, focal adhesion, complement cascade, smooth muscle contraction, and IGF signaling, which have been implicated in both metabolic and brain disorders ([@bb0185], [@bb0085], [@bb0060], [@bb0160], [@bb0175]).

A highlight of the study was the identification of the extracellular matrix genes *Bgn* and *Fmod* as key intermediates of the fructose effects on the gene network and phenotypic alterations, and these findings were corroborated in two knockout mouse models. Small leucine-rich proteoglycans *Fmod* and *Bgn* consistently emerged as KDs in both brain regions for both dietary components, and the expression levels of both genes were also significantly altered by fructose and DHA. *Fmod* and *Bgn* are important structural components of the ECM. The role of the ECM in the regulation of neurite outgrowth, and neural functionality and plasticity ([@bb0075]) as well as metabolic diseases ([@bb0185], [@bb0085], [@bb0045]) is becoming increasingly recognized. Our study provides unique nutrigenomic-based evidence that proteoglycans are likely main orchestrators of important metabolic and cognitive processes in the brain.

To assess the translatability of our rodent findings to human pathophysiology, we found significant intersections between the fructose signatures or the network KDs identified in our rodent models and human GWAS hits for neurological and neurodegenerative diseases, psychiatric diseases, and various metabolic diseases. As human GWAS implies a causal role of the candidate genes based on genetic evidence, the overlapping signatures or network KDs in response to fructose likely play causal roles in the development of MetDs or brain disorders. The same genes also likely mediate the beneficial actions of DHA.

The strength of our study lies in the use of powerful systems nutrigenomic approach to comprehensively characterize phenotypic and multi-tissue transcriptomic and methylomic profiles of fructose and DHA, followed by network modeling, in vivo validation, and human data integration. The highly integrative nature not only enables a comprehensive and in-depth exploration of the molecular mechanisms mediating the actions of nutrition on health and disease, but also pinpoints critical regulators of the biological pathways and provides compelling evidence for the potential causal role of the identified genes and pathways in human diseases.

We note the following limitations of the current study. First, the *Bgn* and *Fmod* KO animals used are not brain-specific. It is possible that the phenotypic changes in peripheral metabolism observed in these models are the results of perturbations of these genes outside of the brain. Future tissue-specific studies are warranted to further investigate the action sites of these ECM genes. Second, the behavioral changes observed in our systemic treatment studies of fructose and DHA as well as in the genetically modified animal models of *Bgn* and *Fmod* could be influenced by numerous variables that are either not investigated or difficult to tease out. Third, we only focused on two brain regions in the current study and future investigations of additional tissues and cell types are warranted.

The staggering increase in the prevalence of MetDs, its negative impact on brain function and pathogenesis of brain disorders, and the role played by fructose consumption as a dietary perturbation in these processes are becoming major concerns for public health and basic and clinical science. Our study provides molecular evidence supporting the ability of fructose to disrupt critical genes and fundamental physiological processes such as insulin, IGF, TLR, TGF beta, BDNF, MAPK, NCAM, and PDGF signaling pathways and neurological processes. The majority of these pathways have been implicated in both MetDs and brain disorders. In addition, genes affected by fructose significantly overlapped with human GWAS genes for brain disorders (e.g., Alzheimer\'s disease, attention deficient hyperactive disorder, depression, addiction, Parkinson\'s disease) and MetDs-related diseases (e.g., blood pressure, cardiovascular disease, lipids, obesity, metabolic syndrome, and T2D). Our results point to the capacity of fructose to reprogram molecular substrates underlying pathology. The remarkable capacity of DHA supplementation to restore genomic, epigenomic, pathway, network, and phenotypic traits vulnerable to the effects of fructose provides multi-level support for the potential of omega-3 fatty acids as a nutritional remedy for metabolic and brain dysregulation. This points to an effective means to guide personalized medicine by matching the disease-promoting molecular signatures with an agent capable of reversing the patterns.

In summary, we show that DHA reverses biological pathways and gene networks perturbed by fructose via transcriptional regulators (such as transcription factors, epigenetic regulators, splicing factors) and essential network regulators (such as *Bgn* and *Fmod*) that may control the balance between health and disease. Our study reveals critical information supporting an action of ECM in orchestrating brain function through gene network organizations. Our experimental validation highlights the predictive power of our systems genomics approaches in identifying vulnerable disease genes and mechanisms. In addition, our paradigm based on the integration between rodent studies and human GWAS serves as a precedent to apply nutrigenomics principles to predict disease susceptibility and to guide personalized medicine.
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![Overall study design and analysis flow.](gr1){#f0005}

![Changes in metabolic and behavior phenotypes, transcriptome, DNA methylome, and biological pathways in response to fructose treatment and DHA supplementation. (a) Metabolic and behavior phenotypes. From left to right: blood glucose, serum triglycerides, serum insulin, insulin resistance index, and latency time in the memory retention probe in the Barnes Maze test. Fructose group was compared with the control group, and the fructose + DHA group was compared to the fructose only group. ^⁎^*p* \< 0.01 and ^\#^*p* \< 0.05 by 2-sided Student\'s *t*-test. Error bars in the plots are standard errors. *N* = 8/group. (b) Heatmap of gene expression changes in hypothalamus and hippocampus. Blue to red colors indicate low to high expression values. (c) Heatmap of DNA methylation changes in hypothalamus and hippocampus. Blue to red colors indicate low to high methylation levels. (d) Select biological pathways affected by fructose and DHA in hypothalamus and hippocampus. Bars are the --log10 enrichment *p* values of the pathways. The insert plot on the right shows the opposite direction of changes in genes in the "focal adhesion" pathway in the hypothalamus between fructose and DHA: fructose mostly inhibits whereas DHA reverses the expression levels. In the insert plot Y-axis indicates log10 fold changes. The fructose + DHA group is labeled as F + D in panels b--d.](gr2){#f0010}

![Gene subnetworks and top network key drivers (KDs) of fructose and DHA. (a) KDs and gene subnetwork in hypothalamus. (b) KDs and gene subnetwork in hippocampus. Larger nodes depict KDs; grey nodes are network genes in the neighborhood of KDs that are not affected by fructose or DHA; top and bottom halves of each node, if colored, denotes genes affected by fructose (top) and DHA (bottom), respectively; red and blue colors denotes increased and decreased expression, respectively. Direction of change for the fructose group is determined by comparison with the control group; direction of change for the DHA + fructose group is determined by comparison with the fructose group.](gr3){#f0015}

![Phenotypic validation of *Bgn* and *Fmod* using knockout (KO) mice. (a) Lipid traits including triglyceride (TG), total cholesterol, HDL cholesterol, un-esterified cholesterol (UC), LDL cholesterol and free fatty acids (FFA). (b) Glucose. (c) Insulin. (d) Insulin resistance (IR) measured by insulin sensitivity index. (e) Intraperitoneal glucose tolerance test (IPGTT). (f) Mistakes made during the Barnes Maze test in four days of the learning phase. (g) Track plots and mistakes made during Barnes Maze test for spatial memory. Two-sided Student\'s *t*-test was used to test statistical difference between knockout mice (*Bgn* KO or *Fmod* KO) and wild-type (WT) mice for analyses in (a)--(g). Two-way ANOVA with Holm-Sidak post hoc analysis for multiple comparisons was performed for the learning curves in panel (f) with \*WT vs. *Bgn* KO; ^\#^*Bgn* KO vs. *Fmod* KO; and ^†^WT vs. *Fmod* KO. Error bars in the plots are standard errors. ^⁎^*p* \< 0.05. Sample size n = 8--16.](gr4){#f0020}

###### 

Overlap between fructose and DHA signatures. Numbers of significant genes or methylation loci are shown. Enrichment *p* value was calculated using 2-sided Fisher\'s exact test.

Table 1

  Data     Tissue         Fructose signature   DHA signature   Overlap   Background   Fold enrichment   *p* value
  -------- -------------- -------------------- --------------- --------- ------------ ----------------- ------------
  RNAseq   Hypothalamus   734                  910             374       17,435       9.76              7.6E − 305
  RNAseq   Hippocampus    206                  569             118       17,411       17.53             1.9E − 124
  RRBS     Hypothalamus   1544                 1665            381       6,686,093    984.54            0
  RRBS     Hippocampus    1872                 1957            557       8,742,773    1329.25           0

###### 

Enrichment of human GWAS signals in fructose signatures and KDs by SNP set enrichment analysis (SSEA).

Table 2

  Tissue                     GWAS disease/trait   GWAS study[a](#tf0005){ref-type="table-fn"}   *p*-Value (KS test)[b](#tf0010){ref-type="table-fn"}   *p*-Value (Fisher\'s exact test[b](#tf0010){ref-type="table-fn"}
  -------------------------- -------------------- --------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------
  Hypothalamus               HDL cholesterol      GLGC                                          **4.35E − 05**                                         **1.25E − 12**
  LDL cholesterol            GLGC                 **1.05E − 03**                                **1.90E − 05**                                         
  Total cholesterol          GLGC                 **8.51E − 06**                                **3.65E − 14**                                         
  Triglycerides              GLGC                 **5.88E − 04**                                **3.09E − 09**                                         
  Diastolic blood pressure   ICBP                 **2.40E − 05**                                **7.55E − 05**                                         
  Systolic blood pressure    ICBP                 **3.06E − 03**                                1.16E − 02                                             
  Type 2 diabetes            DIAGRAM +            2.07E − 02                                    3.39E − 02                                             
  Cognitive function         FHS                  1.78E − 02                                    **3.18E − 03**                                         
  Bipolar disorder           WTCCC                3.06E − 02                                    4.04E − 02                                             
                                                                                                                                                       
  Hippocampus                HDL cholesterol      GLGC                                          **6.48E − 05**                                         **2.02E − 07**
  LDL cholesterol            GLGC                 **2.98E − 05**                                **2.16E − 04**                                         
  Total cholesterol          GLGC                 **2.37E − 05**                                **4.19E − 13**                                         
  Triglycerides              GLGC                 1.34E − 02                                    **6.55E − 06**                                         
  Diastolic blood pressure   ICBP                 4.52E − 01                                    **4.59E − 03**                                         
  Cognitive function         FHS                  9.43E − 03                                    4.28E − 02                                             
  Schizophrenia              CATIE                2.26E − 02                                    3.02E − 01                                             

GLGC: Global Lipids Genetics Consortium; ICBP: The International Consortium for Blood Pressure; DIAGRAM +: The Diabetes Genetics Replication And Meta-analysis Consortium; FHS: Framingham Heart Study; WTCCC: Wellcome Trust Case Control Consortium; CATIE: Clinical Antipsychotic Trials for Intervention Effectiveness.

Bolded *p* values are those passed Bonferroni-corrected *p* \< 0.05.
